Autism symptoms reduced nearly 50% 2 years after fecal transplant | ASU Now: Access, Excellence, Impact
there is hope for you yet tw
In a new study, “Long-Term Benefit of Microbiota Transfer Therapy in Autism Symptoms and Gut Microbiota,” published in Scientific Reports, Arizona State University researchers Rosa Krajmalnik-Brown, James Adams and lead author Dae-Wook Kang demonstrate long-term beneficial effects for children diagnosed with ASD through a revolutionary technique known as Microbiota Transfer Therapy (MTT), a special type of fecal transplant originally pioneered by Australian gastroenterologist Thomas Borody. Remarkably, improvements in gut health and autism symptoms appear to persist long after treatment.
Two years after treatment, most of the initial improvements in gut symptoms remained. In addition, parents reported a slow, steady reduction of ASD symptoms during treatment and over the next two years. A professional evaluator found a 45% reduction in core ASD symptoms (language, social interaction and behavior) at two years post-treatment compared with before treatment began.
...
“Every family completed the study, and every family returned two years later for a follow-up evaluation,” said Adams, citing the families’ dedication to the research. “The treatment was generally well-tolerated with minimal adverse effects.”
...
Professional evaluation revealed a 45% decrease in ASD symptoms compared with baseline. Researchers note that although there may be some placebo effect, much of that effect appears to be real. At the start of the study, 83% of participants were rated as “severe” autism. At the end of the study, only 17% were “severe,” 39% were “mild/moderate” and 44% were below the cutoff for mild ASD.
there is hope for you yet tw